The impact of sodium‐glucose co‐transporter‐2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation

Documenti analoghi

• Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection
  di: Hsiao‐Wei Wang, et al.
  Pubblicazione: (2025)
• A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
  di: Daniel Vincent O'Hara, et al.
  Pubblicazione: (2025)
• Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
  di: Hsiao‐Ling Chen, et al.
  Pubblicazione: (2024)
• Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study
  di: Hui‐Lin Sung, et al.
  Pubblicazione: (2024)
• The Impact of GLP ‐1‐Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta‐Analysis
  di: Shih‐Ming Chuang, et al.
  Pubblicazione: (2026)